Year: 2018
Type: article
Abstract: The outbreak of the Zika virus (ZIKV) has been associated with increased incidence of congenital malformations. Although recent efforts have focused on vaccine development, treatments for infected individuals are needed urgently. Sofosbuvir (SOF), an FDA-approved nucleotide analog inhibitor of the Hepatitis C (HCV) RNA-dependent RNA polymerase (RdRp) was recently shown to be protective against ZIKV both in vitro and in vivo. Here, we show that SOF protected human neural progenitor cells (NPC) and 3D neurospheres from ZIKV infection-mediated cell death and importantly restored the antiviral immune response in NPCs. In vivo, SOF treatment post-infection (p.i.) decreased viral burden in an immunodeficient mouse model. Finally, we show for the first time that acute SOF treatment of pregnant dams p.i. was well-tolerated and prevented vertical transmission of the virus to the fetus. Taken together, our data confirmed SOF-mediated sparing of human neural cell types from ZIKV-mediated cell death in vitro and reduced viral burden in vivo in animal models of chronic infection and vertical transmission, strengthening the growing body of evidence for SOF anti-ZIKV activity.
Source: Scientific Reports
Authors: Pinar Mesci, Angela Macia, Spencer M. Moore, Sergey A. Shiryaev, Antonella Pinto, Chun-Teng Huang, Leon Tejwani, Isabella R. Fernandes, Nicole A. Suarez, Matthew J. Kolar, Sandro Montefusco, Scott C. Rosenberg, Roberto H. Herai, Fernanda R. Cugola, Fabiele B. Russo, Nicholas Sheets, Alan Saghatelian, Sujan Shresta, Jeremiah D. Momper, Jair L. Siqueira-Neto, Kevin D. Corbett, Patricia C. B. Beltrão-Braga, Alexey V. Terskikh, Alysson R. Muotri
Institutions: University of California San Diego, Rady Children's Hospital-San Diego, Sanford Burnham Prebys Medical Discovery Institute, Salk Institute for Biological Studies, Ludwig Cancer Research, Ludwig Cancer Research, Pontifícia Universidade Católica do Paraná, Universidade de São Paulo, La Jolla Institute for Immunology
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,690
Funders: California Institute for Regenerative Medicine, International Rett Syndrome Foundation, Autism Science Foundation, National Alliance for Research on Schizophrenia and Depression, Ludwig Institute for Cancer Research, Rett Syndrome Research Trust, National Institutes of Health, National Institute of Mental Health, National Institute of General Medical Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke
Awards: Characterization of the Diabetes Target Ces3 as an Adipose FAHFA Hydrolase, Host-pathogen interactions in ZIKV infection leading to microcephaly, Collaboration on preclinical autism cellular assays, biosignatures, and network analyses (Copacabana), A treatment for Zika virus infection and neuroprotection efficacy, Medical Scientist Training Program
OpenAlex ID: W2782897656
